Weight Loss Injections Posted or Updated on 22 Jul 2025

✅ What It Covers

• New NHS weight-loss option: Tirzepatide (brand name Mounjaro®) will soon be available via NHS community weight management services launching this summer. NHS Cheshire and Merseyside+15NHS Cheshire and Merseyside+15moretongrouppractice.co.uk+15

• Phased rollout starting 23 June 2025 for eligible patients with the highest health risk. NHS Cheshire and MerseysideCheshire and Merseyside Formulary

🔢 Eligibility Criteria (Cohort 1 – June 2025)

• BMI ≥ 40, or ≥ 37.5 for certain ethnic groups

• Plus at least four of these long-term conditions:

  • Type 2 diabetes

  • Hypertension

  • Dyslipidaemia

  • Cardiovascular disease

  • Obstructive sleep apnoea central.brownlowhealth.co.uk+7NHS Cheshire and Merseyside+7The Middlewood Partnership+7

Subsequent cohorts (2026–27) will expand eligibility:

• Cohort 2 (June 2026): BMI 35–39.9 + ≥4 conditions

• Cohort 3 (April 2027): BMI ≥40 + ≥3 conditions NHS Cheshire and Merseyside+1moretongrouppractice.co.uk+1firdalemedicalcentre.nhs.uk+3Cheshire and Merseyside Formulary+3NHS Cheshire and Merseyside+3

ℹ️ How It Works

• Prescribed as an injection once weekly, alongside structured support for diet and lifestyle changes. NHS Cheshire and Merseyside+1Cheshire and Merseyside Formulary+1

• GLP‑1/GIP agonist that helps control appetite, slow stomach emptying, and assist weight management. Wikipedia+4NHS Cheshire and Merseyside+4NHS Cheshire and Merseyside+4

⏳ What You Should Know

• Not available yet via GPs—wait for community services to launch. Don't contact your GP until official rollout. central.brownlowhealth.co.uk+10NHS Cheshire and Merseyside+10NHS Cheshire and Merseyside+10

• Other GLP‑1 drugs (e.g., Saxenda, Wegovy) remain unavailable via NHS primary care. NHS Cheshire and Merseyside+7NHS Cheshire and Merseyside+7NHS Cheshire and Merseyside+7

Summary

NHS Cheshire & Merseyside is introducing Tirzepatide for weight management, starting this summer, in a phased rollout focused first on adults with a BMI ≥40 (or adjusted lower for some ethnicities) plus multiple health conditions. It will be issued via dedicated community-based services, not direct referral from GPs. Eligibility will broaden over the next two years.

Resource - 

https://www.cheshireandmerseyside.nhs.uk/your-health/prescribing/statements/mounjaro-tirzepatide/